Correlation of Optic Disk Morphology and Ocular Perfusion Parameters in Patients With Primary Open Angle Glaucoma

NCT ID: NCT00803504

Last Updated: 2008-12-05

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 103 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2006-11-30
• Study Completion Date: 2007-08-31

Brief Summary

Glaucoma is one of the most common causes of blindness in the industrialized nations. For a long time glaucoma has been defined as a disease in which high intraocular pressure (IOP) leads to irreversible optic disc damage and subsequent visual field loss. However, recent investigations show that IOP is not the only factor that is involved in the glaucomatous process leading to retinal ganglion cell death. The role of vascular factors in the pathogenesis of glaucoma has recently received much attention based on animal experiments and epidemiological studies. It is, however, assumed that vascular factors do not contribute to same degree in all glaucoma patients. Generally, it is believed that a vascular component is more important in normal tension glaucoma patients and patients with underlying cardiovascular disease. Little is, however, known about a potential association between optic nerve head morphology and ocular perfusion in POAG patients. The current study seeks to gain insight into this association by assessing ocular blood flow parameters with a number of noninvasive technologies.

Conditions

Primary Open Angle Glaucoma

Interventions

ocular blood flow measurement

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Men and women over 18 years
• Unilateral or bilateral primary open angle glaucoma
• At least 3 reliable visual field tests showing CPSD >= 2.0 in the eye that will be studied

Exclusion Criteria

• History of acute angle closure
• Closed or barely open anterior chamber angle
• Standard deviation of visual field testing > 10
• Intraocular surgery or argon laser trabeculoplasty within the last six months
• Ocular inflammation or infection within the last three months
• Topical or systemically/oral therapy with steroids

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medical University of Vienna

OTHER

Sponsor Role: lead

Principal Investigators

Gerhard Garhöfer, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Clinical Pharmacology, Medical University of Vienna

Locations

Deparmtent of Clinical Pharmacology

Vienna, , Austria

Countries

Austria

Other Identifiers

OPHT-120905

Identifier Type: -

Identifier Source: org_study_id